Pharmacologically active compounds that manipulate cellular senescence (senotherapies)
have recently shown great promise in multiple pre-clinical disease models, and some of
them are now being tested in clinical trials. Despite promising proof-of-principle evidence,
there are known on-and off-target toxicities associated with these compounds, and therefore
more refined and novel strategies to improve their efficacy and specificity for senescent cells
are being developed. Preferential release of drugs and macromolecular formulations within …